Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 493

1.

A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.

Sigal BM, Munoz DF, Kurian AW, Plevritis SK.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.

2.

Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

N Engl J Med. 1997 May 15;336(20):1465-71. Erratum in: N Engl J Med 1997 Aug 7;337(6):434.

3.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

4.

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.

Schrag D, Kuntz KM, Garber JE, Weeks JC.

JAMA. 2000 Feb 2;283(5):617-24.

PMID:
10665701
5.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
6.

Online tool to guide decisions for BRCA1/2 mutation carriers.

Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.

J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

7.

Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukel L, Devilee P, van den Ouweland AM, van Geel AN, Klijn JG.

Lancet. 2000 Jun 10;355(9220):2015-20.

PMID:
10885351
8.

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B.

J Clin Oncol. 2004 Mar 15;22(6):1045-54. Epub 2004 Feb 23.

PMID:
14981106
9.

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA.

J Clin Oncol. 2002 Apr 15;20(8):2092-100.

PMID:
11956270
10.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.

Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

PMID:
23232752
11.

Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.

Kurian AW, Sigal BM, Plevritis SK.

J Clin Oncol. 2010 Jan 10;28(2):222-31. doi: 10.1200/JCO.2009.22.7991. Epub 2009 Dec 7.

12.

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.

PMID:
9508180
13.

A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.

Abdollahian M, Das TK.

IEEE J Biomed Health Inform. 2015 Mar;19(2):720-7. doi: 10.1109/JBHI.2014.2319246. Epub 2014 Apr 22.

PMID:
24771600
14.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA.

JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.

PMID:
26181175
15.

Management updates for women with a BRCA1 or BRCA2 mutation.

Nusbaum R, Isaacs C.

Mol Diagn Ther. 2007;11(3):133-44. Review.

PMID:
17570734
16.
17.

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA.

J Clin Oncol. 2005 Oct 20;23(30):7491-6.

PMID:
16234515
18.

Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.

Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.

Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.

PMID:
23487443
19.

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.

Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.

Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053.

PMID:
18269778
20.

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.

This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D; Institut Curie Breast and Ovarian Cancer Risk Study Group.

Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.

PMID:
22711610

Supplemental Content

Support Center